Evidence map›Paper›PMID 38947012›Full record

ArticleResearch square2024

Anti-tumor Effects of the eIF4A Inhibitor Didesmethylrocaglamide and Its Derivatives in Human and Canine Osteosarcomas.

Janet Oblinger, Jack Wang, Georgia Wetherell, Garima Agarwal, Tyler Wilson, Nicole Benson, Joelle Fenger, James Fuchs, A Douglas Kinghorn, Long Chang

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Janet OblingerAbigail Wexner Research Institute at Nationwide Children's Hospital.
Jack WangAbigail Wexner Research Institute at Nationwide Children's Hospital.
Georgia WetherellAbigail Wexner Research Institute at Nationwide Children's Hospital.
Garima AgarwalThe Ohio State University.
Tyler WilsonThe Ohio State University.
Nicole BensonThe Ohio State University.
Joelle FengerThe Ohio State University.
James FuchsThe Ohio State University.
A Douglas KinghornThe Ohio State University.
Long ChangAbigail Wexner Research Institute at Nationwide Children's Hospital.

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
Project 3:Isolation Chemistry of Filamentous Fungi and Biological EvaluationP01CA125066 · NCI · OHIO STATE UNIVERSITY · PI JIMMY ORJALA · 2007 to 2026
$27.2M
NCI NIH HHS P01 CA125066NCI NIH HHS P30 CA016058
6 · The paper itself

Abstract

Inhibition of translation initiation using eIF4A inhibitors like (-)-didesmethylrocaglamide [(-)-DDR] and (-)-rocaglamide [(-)-Roc] is a potential cancer treatment strategy as they simultaneously diminish multiple oncogenic drivers. We showed that human and dog osteosarcoma cells expressed high levels of eIF4A1/2, particularly eIF4A2. Genetic depletion of eIF4A1 and/or 2 slowed osteosarcoma cell growth. To advance preclinical development of eIF4A inhibitors, we demonstrated the importance of (-)-chirality in DDR for growth-inhibitory activity. Bromination of DDR at carbon-5 abolished growth-inhibitory activity, while acetylating DDR at carbon-1 was tolerated. Like DDR and Roc, DDR-acetate increased the γH2A.X levels and induced G

Indexed as

didesmethylrocaglamide (DDR)eIF4A inhibitorOsteosarcomap38 stress-activated protein kinaseRhoBrocaglamide (Roc)

Identifiers

PMID38947012
PMCPMC11213195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.